API | itolizumab

itolizumab Report issue

Biologics mAb Experimental

Active Ingredient History

NOW

Itolizumab is a 'first in class' humanized IgG1 monoclonal antibody developed by Biocon and the Center of Molecular Immunology (CIM), Havana. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: No
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Organizations (6)

Research & Development (6)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)

Asthma (Phase 1)

Coronavirus (Phase 3)

COVID-19 (Phase 2)

Cytokine Release Syndrome (Phase 2)

Dermatomyositis (Phase 1)

Graft vs Host Disease (Phase 3)

Lupus Erythematosus, Systemic (Phase 1)

Lupus Nephritis (Phase 1)

Respiratory Distress Syndrome (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial Organizations: 6

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue